• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Involvement of Sytl1-mediated AML exosomes in AML leukemogenesis

Research Project

Project/Area Number 18K16100
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 54010:Hematology and medical oncology-related
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

Sunami Yoshitaka  公益財団法人がん研究会, がん研究所 発がん研究部, 研究員 (50732864)

Project Period (FY) 2018-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords急性骨髄性白血病(AML) / 骨髄生着 / Hoxa9 / Meis1 / Sytl1 / shRNAスクリーニング / 急性骨髄性白血病 / エクソソーム / 骨髄微小環境
Outline of Final Research Achievements

Synaptotagmin-like 1 (Sytl1, also known as Slp1) was identified as a target gene of Meis1, a transcriptional factor which plays a critical role in AML development. In this project, we attempted to clarify the model that Sytl1 regulated the secretion of exosomes, and subsequently promotes the engraftment of AML cells into the bone marrow. However, the experiment using Slp1-knock out mouse revealed that the function of Sytl1 in the engraftment of AML cells was limited in non-Meis1 associated AML. Therefore, to identify the critical factor for the AML cell engraftment, we performed a whole-genome lentiviral shRNA screening followed by the second screening using custom made sgRNA libraries. Finally, we identified 37 candidate genes that could be associated with the engraftment of AML cells.

Academic Significance and Societal Importance of the Research Achievements

AMLは高率に再発し、その原因として骨髄定着したAML細胞が治療後も残存することが挙げられるが、AML細胞が骨髄定着する分子基盤は明らかでない。本研究で同定した標的候補遺伝子はAML細胞の骨髄定着に重要な役割を果たしている可能性があり、したがって本研究成果は学術的に意義がある。また、これらの遺伝子を標的とした新規治療法を開発することで、治療後のAML残存病変を駆逐し、AML再発や治療抵抗性獲得を克服することが期待できる。さらには同定した遺伝子を特異的な治療標的とすることで、大きな副作用のない再発予防が実現でき、AML患者のQOLを改善することが可能となるため、本研究成果の社会的意義も高い。

Report

(3 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • Research Products

    (10 results)

All 2020 2019 2018

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (9 results) (of which Int'l Joint Research: 2 results)

  • [Journal Article] Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation2018

    • Author(s)
      Araki Marito、Yang Yinjie、Imai Misa、Mizukami Yoshihisa、Kihara Yoshihiko、Sunami Yoshitaka、Masubuchi Nami、Edahiro Yoko、Hironaka Yumi、Osaga Satoshi、Ohsaka Akimichi、Komatsu Norio
    • Journal Title

      Leukemia

      Volume: 33 Issue: 1 Pages: 122-131

    • DOI

      10.1038/s41375-018-0181-2

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] BCL11AによるPU.1機能阻害2020

    • Author(s)
      角南義孝、芳野聖子、横山隆志、中村卓郎
    • Organizer
      第24回 造血器腫瘍研究会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Bcl11a promotes AML development and progression through the abrogation of PU . 1 activity2019

    • Author(s)
      Sunami Y, Yoshino S, Yokoyama T, Nakamura T.
    • Organizer
      第78回 日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Bcl11aはPU.1の転写活性阻害を介してAMLの発症、悪性化を促進する2019

    • Author(s)
      角南義孝、中村卓郎
    • Organizer
      第81回日本血液学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Bcl11a promotes AML development and progression through the abrogation of PU.1 activity2019

    • Author(s)
      Sunami Y, Yoshino S, Yokoyama T, Nakamura T.
    • Organizer
      FASEB Hematologic Malignancies Conference
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Bcl11a promotes AML development through the abrogation of PU.1 activity.2019

    • Author(s)
      Sunami Y, Yoshino S, Yokoyama T, Nakamura T.
    • Organizer
      11th AACR-JCA Joint Conference
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Bcl11aによるAML発症、悪性化機序の解明2019

    • Author(s)
      角南義孝, 中村卓郎
    • Organizer
      第23回 造血器腫瘍研究会
    • Related Report
      2018 Research-status Report
  • [Presentation] Gene expression profiles in ATRA-induced granulocytic differentiation.2018

    • Author(s)
      Sunami Y, Araki M, Yamamoto S, Horiuchi Y, Tsujioka K, Mogushi K, Imai M, Morishita S, Ohsaka A, Komatsu N.
    • Organizer
      第80回 日本血液学会学術集会
    • Related Report
      2018 Research-status Report
  • [Presentation] Bcl11a promotes Trib1-induced myeloid leukemia development.2018

    • Author(s)
      Sunami Y, Yoshino S, Yokoyama T, Nakamura T.
    • Organizer
      第77回 日本癌学会学術総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Bcl11aのAML発症における役割の解明2018

    • Author(s)
      角南義孝, 芳野聖子, 横山隆志, 中村卓郎.
    • Organizer
      平成30年度若手支援技術講習会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi